TenNor publishes article on TNP-2092 PO Potential Application in the Treatment of Gastrointestinal and Liver Disorders in ACS Infectious Disease.

Please read the article through this link：https://pubs.acs.org/doi/abs/10.1021/acsinfecdis.9b00374

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late-stage of clinical development targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com